Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- AT-301
- DrugBank Accession Number
- DB16507
- Background
AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Not Available
- External IDs
- AT-301
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
AT-301 is a proprietary nasal formula developed by Atossa intended for administration in patients diagnosed with COVID-19 who do not have symptoms severe enough for hospitalization. This formulation aims to prevent infection by potentially interfering with spike protein activation through host proteases, by masking receptor binding domains, and by providing a generalized mucoadhesive epithelial barrier to block the entry of the SARS-CoV-2 viral gene proteins in the nasal epithelial cells. AT-301 is currently being investigated against COVID-19.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Completed Prevention Influenza A(H5N1) / Influenza, Avian 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 02:02 / Updated at July 13, 2024 15:36